BackgroundThe CD5 protein antagonizes phosphorylation events downstream of T cell receptor (TCR) engagement to decrease T cell responsiveness. CD5-negative T cell clones respond preferentially over their CD5+ counterparts against cells with low human histocompatibility-linked leukocyte antigen (HLA) levels. In human immunodeficiency virus type 1 (HIV-1) infection, CD5-CD8+ T cells increase in prevalence with disease progression.MethodsTo investigate potential causes of this expansion of CD5-CD8+ T cells in HIV-1 infection, we compared CD5 expression on CD8+ T cells reactive against HIV-1 peptides, common viral peptides and a self peptide that together span a broad range of TCR avidities in the context of the common HLA-A2 class I restriction molecule. Following stimulation, CD5 expression on peptide-specific CD8+ T cells was assessed by flow cytometry.ResultsIn healthy controls, there was no significant difference in the CD5+ percentage of CD8+ T cells specific for common viral peptides, but a lower percentage of those responding against a common self peptide expressed CD5. The same relationship occurred in HIV-infected individuals, however, a lower percentage of HIV peptide-specific CD8+ T cells than other viral peptide-specific CD8+ T cells expressed CD5. In terms of overall CD5 expression level at the peptide-specific responder population level, HIV-specific CD8+ T cells resembled those responsive against the self peptide, despite much higher avidity TCR/HLA/peptide interactions.ConclusionsThis deficit in CD5 expression selective for HIV-specific CD8+ T cells is consistent with in vivo adaptation to low avidity HIV peptide variants and has potential consequences for CD8+ T cell expansion, cross-reactivity and autoreactivity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.